Aerie Pharmaceuticals Inc. (NASDAQ:AERI) had its price objective boosted by Stifel Nicolaus from $50.00 to $55.00 in a report released on Thursday morning. The firm currently has a buy rating on the stock.
AERI has been the subject of several other research reports. Raymond James Financial Inc. initiated coverage on Aerie Pharmaceuticals in a research note on Tuesday, September 13th. They set an outperform rating and a $48.00 target price for the company. Brean Capital restated a buy rating and set a $48.00 target price on shares of Aerie Pharmaceuticals in a research note on Wednesday, September 7th. Needham & Company LLC restated a buy rating and set a $45.00 target price on shares of Aerie Pharmaceuticals in a research note on Tuesday, August 23rd. RBC Capital Markets restated an outperform rating and set a $55.00 target price (up previously from $51.00) on shares of Aerie Pharmaceuticals in a research note on Friday, September 16th. Finally, Zacks Investment Research cut Aerie Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, October 4th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $51.40.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 39.74 on Thursday. The firm has a 50-day moving average price of $29.77 and a 200 day moving average price of $19.95. The stock’s market cap is $1.11 billion. Aerie Pharmaceuticals has a 52-week low of $10.82 and a 52-week high of $41.72.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.02. Analysts expect that Aerie Pharmaceuticals will post ($2.81) earnings per share for the current year.
In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, October 6th. The stock was sold at an average price of $40.34, for a total value of $2,017,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 8.77% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AERI. Barclays PLC raised its position in Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock worth $106,000 after buying an additional 200 shares during the last quarter. First Mercantile Trust Co. bought a new position in Aerie Pharmaceuticals during the third quarter worth about $161,000. BlackRock Advisors LLC raised its position in Aerie Pharmaceuticals by 15.0% in the second quarter. BlackRock Advisors LLC now owns 12,310 shares of the company’s stock worth $217,000 after buying an additional 1,608 shares during the last quarter. GSA Capital Partners LLP bought a new position in Aerie Pharmaceuticals during the second quarter worth about $219,000. Finally, American International Group Inc. raised its position in Aerie Pharmaceuticals by 8.5% in the second quarter. American International Group Inc. now owns 13,864 shares of the company’s stock worth $244,000 after buying an additional 1,082 shares during the last quarter. 95.22% of the stock is currently owned by institutional investors and hedge funds.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.